NXL

Nexalin Technology, Inc.

$1.47

-2.00%
SectorHealthcareIndustryMedical DevicesCountryUnited States

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.

Source: Yahoo Finance
AI summary

Price & performance

1M-73.7%
3M-85.2%
YTD-91.4%
1Y-96.7%
52-week range—
Beta1.38
Full chart and returns against a benchmark

Q-Score

30/ 100

Quality against peers; 50 is the peer median.

Growth37
Risk28
Performance58
Valuation15
Profitability36
Leverage22
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$301.6K+78.8%
Net income-$8.2M
Net margin—
Historical fundamentals

Red flags in filings

4active red flags
Going-concern doubtMar 25, 2026
Material weakness in controlsMar 25, 2026
Auditor changeApr 17, 2025
Filings, findings and the timeline

Revenue exposure

63%of revenue from outside the US
China63%
United States37%
Regions, segments, customers and suppliers

Valuation

NXLIndustryP/E—29.61P/S7.783.49EV/EBITDA—18.38P/B1.113.39PEG——
Dividend yield0.00%
Every valuation metric